Trinity Biotech PLCNASDAQ:TRIBNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.1600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.1000/ 2
- Ask / Lots1.2800/ 1
- Open / Previous Close--- / 1.1600
- Day Range---
- 52 Week Range
- Volume1
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TRIB |
|---|---|---|
| 09:32 ET | 1072 | 1.19 |
| 09:36 ET | 1184 | 1.16 |
| 09:38 ET | 5000 | 1.1899 |
| 09:43 ET | 500 | 1.1625 |
| 09:52 ET | 2000 | 1.1601 |
| 09:54 ET | 2000 | 1.175 |
| 10:03 ET | 2000 | 1.1812 |
| 10:10 ET | 5000 | 1.175 |
| 10:14 ET | 1181 | 1.162 |
| 10:19 ET | 550 | 1.174 |
| 10:46 ET | 540 | 1.174 |
| 10:48 ET | 200 | 1.18 |
| 10:50 ET | 400 | 1.18 |
| 10:57 ET | 200 | 1.17 |
| 11:08 ET | 501 | 1.17 |
| 11:11 ET | 150 | 1.1706 |
| 11:24 ET | 1000 | 1.17 |
| 11:36 ET | 500 | 1.1765 |
| 11:38 ET | 1100 | 1.1767 |
| 11:40 ET | 1000 | 1.1799 |
| 11:42 ET | 821 | 1.18 |
| 11:44 ET | 1300 | 1.18 |
| 11:51 ET | 1000 | 1.1747 |
| 11:58 ET | 400 | 1.1729 |
| 12:03 ET | 542 | 1.17 |
| 12:41 ET | 265 | 1.1699 |
| 01:26 ET | 227 | 1.17 |
| 01:28 ET | 984 | 1.17 |
| 01:32 ET | 250 | 1.16 |
| 01:33 ET | 330 | 1.16 |
| 01:35 ET | 600 | 1.16 |
| 01:37 ET | 600 | 1.16 |
| 01:42 ET | 700 | 1.16 |
| 01:46 ET | 600 | 1.16 |
| 01:50 ET | 3395 | 1.1666 |
| 02:02 ET | 4672 | 1.163 |
| 02:15 ET | 101 | 1.15 |
| 02:36 ET | 100 | 1.15 |
| 02:40 ET | 475 | 1.15 |
| 02:42 ET | 1000 | 1.155 |
| 02:49 ET | 200 | 1.15 |
| 03:14 ET | 100 | 1.16 |
| 03:16 ET | 1500 | 1.17 |
| 03:23 ET | 200 | 1.18 |
| 03:57 ET | 102 | 1.1615 |
| 03:59 ET | 354 | 1.16 |
Sep 24, 2024
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market, from 4:05PM ET on Tuesday Sep 24, 2024 by Dow Jones
4:05PM ET on Tuesday Sep 24, 2024 by Dow Jones*DJ Trinity Biotech Announces Acquisition Of Metabolomics Diagnostics To Grow Presence In Maternal Health Market >TRIB, from 4:05PM ET on Tuesday Sep 24, 2024 by Dow Jones
4:05PM ET on Tuesday Sep 24, 2024 by Dow Jones
Sep 18, 2024
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer, from 4:05PM ET on Wednesday Sep 18, 2024 by Dow Jones
4:05PM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 9, 2024
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology, from 4:05PM ET on Monday Sep 09, 2024 by Dow Jones
4:05PM ET on Monday Sep 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Trinity Biotech PLC | 13.2M | -0.4x | --- |
Minerva Surgical Inc | 10.0 | 0.0x | --- |
Retractable Technologies Inc | 22.3M | -1.2x | --- |
Sonendo Inc | 3.4M | -0.1x | --- |
Dalrada Financial Corp | 12.1M | -0.5x | --- |
Apyx Medical Corp | 42.3M | -1.5x | --- |
Company Information
Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide.
Contact Information
- Headquarters
- Ida Business Park Bray, Co Wicklow, IrelandBRAY, Ireland 18
- Phone
- ---
- Fax
- ---
Executives
- President, Chief Executive Officer, Executive Director
- John Gillard
- Chief Executive Officer, Executive Director
- Ronan O'caoimh
- Chief Financial Officer, Chief Accounting Officer
- Louise Tallon
- Chief Technology Officer
- Gary Keating
- Chief Information Officer
- Eibhlin Kelly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.2M |
|---|---|
Revenue (TTM) | $58.7M |
Shares Outstanding | 2.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.21 |
EPS | $-2.74 |
Book Value | $-15.67 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 0.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -26.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
